Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Prolific announces major new investments and partnerships with NantWorks and Zylidac Bio CDMO (opens in a new tab)

news-medical.net · 2026-10-28

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

18 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

The literature search

18 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 14 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 5Not checkedProlific Machines announced a new partnership with Zylidac Bio to scale production of its Optogentics-enabled cell lines for clinical and GMP manufacturing.View evidenceHide evidence

As statedscale up production for clinical and GMP manufacturing

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 5Not checkedProlific announced a major investment to scale its optogenetics platform for biomanufacturing and expand programs across biologics, biosimilars, viral vectors, and early tissue and organ fabrication work.View evidenceHide evidence

As statedmajor investment

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 5Not checkedThe company says its technology has already shown success at development scale with industry-leading yields across mAbs and difficult-to-express proteins, and the next step is scaling it to GMP production for clinical and commercial supply.View evidenceHide evidence

As statedindustry-leading yields

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 5Not checkedThe investment is led by Atoms & Bits and Nant Capital.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 5Not checkedProlific Machines and NantWorks announced a strategic collaboration to apply Prolific's platform across biologic programs within NantWorks' portfolio companies.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

THE LARGE SCALE CULTIVATION OF HYBRIDOMA CELLS PRODUCING MONOCLONAL ANTIBODIES

Large-scale Mammalian Cell Culture · 1985 · Crossref

Source (opens in a new tab)

Explore all search results